Compare Novavax Inc (NVAX) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs PepsiCo, Inc. — how do they compare? Novavax Inc trades at $8.11 (market cap $1.30B), while PepsiCo, Inc. trades at $135.04 (market cap $184.89B). The key difference: PepsiCo, Inc. is far larger — about 142.2× Novavax Inc's market cap, and PepsiCo, Inc. pays a 4.37% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | PEP | |
|---|---|---|
Market Cap | $1.30B | $184.89B |
Sector | Health | Consumer Staples |
52-Week High | $11.19 | $170.44 |
52-Week Low | $6.22 | $135.40 |
Enterprise Value | $800.50M | $227.39B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
PepsiCo (PEP) trades at $134.98, down 1.56% today, with a bearish technical signal as moving averages indicate selling pressure. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $93.93B in 2025, though net income margin dipped to 8.77%. Analysts maintain a consensus price target of $158.50, implying upside, while recent news highlights price cuts on snacks to address consumer pushback on high costs.
The outlook for PEP is mixed; strong cash flow and dividend payments support income investors, but margin pressure and competitive risks persist. Upside depends on North American performance recovery and effective pricing strategy execution. Key risks include consumer sensitivity to price hikes and macroeconomic headwinds affecting discretionary spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
